Posts by Mourabit Halima

At the recent The 9th Congress of the Chinese Chapter of the International Hepato-Pancreato-Biliary Association (CCIHPBA), Prof. Chaoliu Dai from Shengjing Hospital of China Medical University presented on “Controlling Intraoperative Hemorrhage and Protecting Residual Liver Function in Hepatectomy.” Oncology frontier invited Prof. Dai to delve further into this topic and share insights from his presentation.

The 2024 CACA Integrated Lung Cancer Conference, hosted by the Chinese Anti-Cancer Association, was held in Zhuhai from October 25 to 26. Focusing on the theme “Gathering Strength, Leading the Future,” the conference brought together prominent experts in the field of lung cancer to discuss critical issues and advancements. Oncology frontier interviewed Dr. Weimin Li from West China Hospital, Sichuan University, who shared insights on the progress and future outlook of precision lung cancer screening in China.

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has successfully concluded, showcasing groundbreaking oncology research. Dr. Chang Liu from Professor Lin Shen’s team at Peking University Cancer Hospital presented their study on the efficacy and safety of CCR8 monoclonal antibody LM-108 combined with PD-1 antibody in gastric cancer patients. Professor Shen’s presentation at ASCO sparked significant industry interest. Oncology Frontier invited Dr. Chang Liu to provide an in-depth analysis of this study’s breakthroughs and significance.

The 9th Academic Symposium of the Chinese Branch of the International Hepato-Pancreato-Biliary Association (IHPBA) was held in Wuhan from October 25-27, 2024, drawing renowned experts from over 20 countries, including the United States, Germany, France, Russia, and Australia. With more than 50 prominent international scholars, 21 academicians, and over 700 experts in liver, gallbladder, and pancreas oncology, the symposium provided a platform to discuss the latest advancements and standards in liver cancer diagnosis and treatment. Dr. Tianqiang Song from Tianjin Medical University Cancer Institute and Hospital delivered an insightful presentation on “Advancements in Perioperative Treatments for Liver Cancer and the Tianjin Experience.” In a joint interview with Oncology Frontier, Professor Song shared insights into perioperative treatment research and practical experiences.

From October 17 to 19, 2024, the 18th National Breast Cancer Conference and the 19th Shanghai International Breast Cancer Symposium (SIBCS 2024) took place in Shanghai. During this period, the fourth Controversy & Consensus Consortium (3C) Summit, focusing on clinical practice in Chinese breast cancer, was successfully held. Leading breast cancer experts and patient representatives participated in discussions and voting on updates for the 2025 CBCS Guidelines “Little Red Book.”